Cosmos Health COSM

NASDAQ COSM
$3.24 +3.03 (+1,442.86%)
At close: Nov 13, 2026 · 4:00 PM EST

Cosmos Health (COSM) stock price is $3.24, up 1,442.86% on the day, as of Nov 13, 2026. It has a market cap of $9.71Mn, and is classified in the Generic Drugs industry (Healthcare sector).

Key Stats
Market Cap9.71 Mn
P/E-7.96
FCF (Yr)-8.50 Mn
ROA (Yr)-27.85
EV to EBIT-0.31
Net Income (Yr)-19.14 Mn
Enterprise Value5.64 Mn
Add ratio to table…

About

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group that owns proprietary pharmaceutical and nutraceutical brands, manufactures and distributes generic and innovative medicines, produces biocides and medical devices, develops drug repurposing solutions and operates a telehealth platform. The company generates revenue from the sale of generic pharmaceuticals, nutraceutical supplements, biocide products, oncology drug candidates, licensing of…

Read more ↓
Sector: Healthcare Sector rationale The company's dominant business lines are the manufacture and sale of generic pharmaceuticals, oncology drugs, biocides, and medical devices, as well as operating a telehealth platform. A secondary sector of Technology is justified because the company sells licenses for its proprietary Cloudscreen® AI drug repurposing platform, which is a distinct software-based revenue stream. Industries: +2 more Generic Drugs Generic Drugs Primary The company's primary business includes the development, manufacture, and sale of generic pharmaceutical products such as ASTO-CHOL, Diorium, and LIPICHOL. It operates a dedicated 'Generic Medicines' segment and serves retail pharmacies, hospitals, and wholesalers. Telehealth Telehealth Secondary The company operates the ZipDoctor platform, which is a direct-to-consumer subscription service providing 24/7 remote access to board-certified physicians and mental-health counsellors. Contract Manufacturing Contract Manufacturing Secondary Cosmos Health generates revenue from contract manufacturing for third parties, utilizing its GMP and EMA manufacturing licenses. Classified using BQ-MICS CIK: 0001474167

Income Tax Authority Name Axis Breakdown of Revenue (2025)

History

Statement Business Segments Axis Breakdown of Revenue (2025)

History
Peer percentiles

How Cosmos Health ranks

Ranked against the 695 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 14, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/ENegative earnings −7.96xMedian 17.0x 65th
  • P/FCFNegative free cash flow −0.98xMedian 19.0x 21st
  • P/Operating cash flowNegative operating cash flow −0.99xMedian 16.4x 22nd
  • P/S 0.13xMedian 8.38x 97th
  • P/B 0.47xMedian 2.04x 86th
  • P/Tangible book 0.71xMedian 2.31x 82nd
  • EV/EBITDANegative EBITDA −1.36xMedian 14.6x 29th
  • EV/EBITNegative EBIT −1.25xMedian 18.4x 29th
  • EV/Revenue 0.31xMedian 6.34x 97th
  • EV/FCFNegative free cash flow −2.32xMedian 23.4x 32nd
  • EV/Operating cash flowNegative operating cash flow −2.34xMedian 19.3x 32nd
  • PEG (3Y EPS CAGR)Negative earnings −0.15Median 0.43 Not meaningful —
Peer group

Peer Comparison

Companies in the Generic Drugs
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 LLY ELI LILLY & Co 1,359.75 Bn46.7415.7349.50 Bn
2 JNJ Johnson & Johnson 688.76 Bn42.836.9344.65 Bn
3 ABBV AbbVie Inc. 521.69 Bn50.487.9080.90 Bn
4 MRK Merck & Co., Inc. 364.31 Bn148.685.4153.78 Bn
5 NVS Novartis Ag 306.35 Bn17.915.08-
6 AZN Astrazeneca Plc 285.96 Bn25.924.82-6.68 Bn
7 AMGN Amgen Inc 251.88 Bn26.836.4754.01 Bn
8 COSM Cosmos Health Inc. 0.01 Bn-7.960.130.02 Bn